OGEN ORAGENICS INC
Pharmaceutical Preparations · NYSE · SEC CIK 1174940 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY11.8%
TTM EPS YoY-102.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-176.1%
ROA-120.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets66.7%
Debt / equity0.00x
Current ratio—
Interest coverage-547.81x
Cash quality & payout
Operating cash flow / net income0.96x
Accruals ratio-4.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $2.39M | $4.11M |
| SG&A expense | $6.97M | $6.44M |
| Operating income | -$9.36M | -$10.56M |
| Interest expense | $785,930 | $29,828 |
| Pretax income | -$9.98M | -$10.57M |
| Income tax | -$136,910 | — |
| Net income | -$9.84M | -$10.57M |
| EPS (basic) | -4.56 | -47.88 |
| EPS (diluted) | -4.56 | -47.88 |
| Weighted avg. shares (diluted) | 2.16M | 220,731 |
| Balance sheet | ||
| Cash & equivalents | $4.40M | $864,840 |
| Short-term investments | $4.00M | — |
| Current assets | $10.07M | $1.47M |
| Total assets | $10.07M | $1.47M |
| Total liabilities | $1.79M | $1.68M |
| Shareholders' equity | $8.28M | -$211,885 |
| Shares outstanding | 4.27M | 419,003 |
| Cash flow statement | ||
| Operating cash flow | -$9.25M | -$8.60M |
| Financing cash flow | $16.78M | $5.98M |
| Stock-based compensation | $642,364 | $516,049 |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.